Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-04-29T12:28:18.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The page has undergone significant content removal, particularly regarding the details of a clinical study for telisotuzumab vedotin in treating non-small cell lung cancer, including eligibility criteria and study phases. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.
    Difference
    14%
    Check dated 2025-04-22T09:01:51.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-07T23:28:04.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.0%
    Check dated 2025-03-31T20:03:51.000Z thumbnail image
  7. Check
    79 days ago
    Change Detected
    Summary
    The web page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.6%
    Check dated 2025-02-19T15:58:21.000Z thumbnail image
  8. Check
    86 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.6%
    Check dated 2025-02-12T09:29:05.000Z thumbnail image

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.